AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37704299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational Atherectomy (RA)
Number of subjects: 0
Study 37704299 — intervention group
Group type: COMPARATOR
Intervention: Orbital Atherectomy (OA)
Number of subjects: 0
Study 37704299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RA and OA
Number of subjects: 0
Study 33547228 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MRI inflammation
Number of subjects: 218
Study 33547228 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ultrasound inflammation
Number of subjects: 218
Study 33547228 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging inflammation in clinical remission
Number of subjects: 218
Study 33547228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenosynovitis
Number of subjects: 218
Study 33547228 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovitis and tenosynovitis
Number of subjects: 218
Study 33547228 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging information
Number of subjects: 218
Study 35639873 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel sandblasting
Number of subjects: 197
Study 35639873 — intervention group
Group type: COMPARATOR
Intervention: Non-sandblasting (control)
Number of subjects: 197
Study 35639873 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 197
Study 35639873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair level of co‐operation
Number of subjects: 197
Study 33415354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 362
Study 33415354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 362
Study 32621047 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 358
Study 32621047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 358
Study 32621047 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide-plus-acarbose
Number of subjects: 358
Study 34983508 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE lifestyle intervention (12-month group-based intervention focusing on increased physical activity and healthy food intake)
Number of subjects: 15
Study 34983508 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE lifestyle intervention
Number of subjects: 15
Study 32871761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh group
Number of subjects: 3
Study 32871761 — intervention group
Group type: COMPARATOR
Intervention: 5% DMSO group
Number of subjects: 3
Study 32871761 — intervention group
Group type: COMPARATOR
Intervention: 10% DMSO group
Number of subjects: 3
Study 32871761 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups at 1st passage
Number of subjects: 3
Study 32871761 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups at 3rd passage
Number of subjects: 3
Study 35603236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 68
Study 35603236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 33036322 — intervention group
Group type: EXPERIMENTAL
Intervention: Random allocation of subcarriers in an OFDM-based CRN without spectrum-sensing mechanism
Number of subjects: 0
Study 33036322 — intervention group
Group type: EXPERIMENTAL
Intervention: M-QAM modulation orders
Number of subjects: 0
Study 33036322 — intervention group
Group type: EXPERIMENTAL
Intervention: Different modulation orders of M-QAM
Number of subjects: 0
Study 35596784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (oral and intravenous glucose, target blood glucose > 25 mM for 2 hours)
Number of subjects: 21
Study 35596784 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (administered on day 3)
Number of subjects: 21
Study 35596784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered on day 1)
Number of subjects: 21
Study 34020929 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-F transradial access (TRA)
Number of subjects: 388
Study 34020929 — intervention group
Group type: COMPARATOR
Intervention: 7-F transfemoral access (TFA)
Number of subjects: 388
Study 32611442 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Breathing Exercises (VBE)
Number of subjects: 140
Study 32611442 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (Control)
Number of subjects: 140
Study 35217325 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga for HEART
Number of subjects: 15
Study 35217325 — intervention group
Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 15
Study 33010810 — intervention group
Group type: EXPERIMENTAL
Intervention: as-needed budesonide–formoterol 200–6 μg
Number of subjects: 5721
Study 33010810 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide maintenance 200 μg twice daily plus as-needed terbutaline
Number of subjects: 5721
Study 33010810 — intervention group
Group type: COMPARATOR
Intervention: as-needed terbutaline 0.5 mg
Number of subjects: 5721
Study 35126880 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Number of subjects: 59
Study 35126880 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment As Usual (ETAU)
Number of subjects: 59
Study 33709262 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope™ videolaryngoscopy (GVL)
Number of subjects: 50
Study 33709262 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy using a Macintosh blade (MAC)
Number of subjects: 50
Study 33709262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GVL and MAC
Number of subjects: 50
Study 32902572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-stored platelets (2° to 6°C)
Number of subjects: 40
Study 32902572 — intervention group
Group type: COMPARATOR
Intervention: Room temperature-stored platelets (20° to 24°C)
Number of subjects: 40
Study 32902572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-stored platelets (8 to 14 days)
Number of subjects: 40
Study 36433897 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster intervention delivered remotely by telephone in one session.
Number of subjects: 50
Study 35035229 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository Diclofenac 100mg
Number of subjects: 0
Study 35035229 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (5% Prilocaine/Lidocaine)
Number of subjects: 0
Study 35035229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34043401 — intervention group
Group type: EXPERIMENTAL
Intervention: personalized feedback plus interactive text messaging (PFT)
Number of subjects: 77
Study 34043401 — intervention group
Group type: EXPERIMENTAL
Intervention: personalized feedback only (PF)
Number of subjects: 77
Study 34043401 — intervention group
Group type: COMPARATOR
Intervention: informational control (IC)
Number of subjects: 77
Study 32510635 — intervention group
Group type: EXPERIMENTAL
Intervention: cord-RBCs
Number of subjects: 25
Study 32510635 — intervention group
Group type: COMPARATOR
Intervention: adult-RBCs
Number of subjects: 25
Study 32510635 — intervention group
Group type: COMPARATOR
Intervention: combined adult- and cord-RBCs
Number of subjects: 25
Study 34764195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Pembrolizumab for one year
Number of subjects: 1301
Study 34764195 — intervention group
Group type: COMPARATOR
Intervention: High-dose IFNα-2b for one year
Number of subjects: 1301
Study 34764195 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab for up to three years
Number of subjects: 1301
Study 34764195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Pembrolizumab
Number of subjects: 1301
Study 34764195 — intervention group
Group type: COMPARATOR
Intervention: High-dose IFNα-2b
Number of subjects: 1301
Study 34764195 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 1301
Study 34321730 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Care Interventional Package
Number of subjects: 115
Study 34321730 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 115
Study 34958368 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 58
Study 32065311 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing for CPs and CPns
Number of subjects: 40
Study 32065311 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene tutoring for CHs and CHns
Number of subjects: 40
Study 35764194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise-based lifestyle intervention (5-6 aerobic sessions/week, 2-3 resistance training sessions/week, dietary intervention aiming at reduction of ∼500 kcal/day for months 0-4, isocaloric diet for months 5-12)
Number of subjects: 77
Study 35764194 — intervention group
Group type: COMPARATOR
Intervention: Standard care (individual education in diabetes management, advice on healthy lifestyle, medication regulation by a blinded endocrinologist)
Number of subjects: 77
Study 35764194 — intervention group
Group type: EXPERIMENTAL
Intervention: Between group comparison
Number of subjects: 77
Study 35764194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 33582306 — intervention group
Group type: EXPERIMENTAL
Intervention: DilaCheck (novel device)
Number of subjects: 42
Study 33582306 — intervention group
Group type: COMPARATOR
Intervention: Standard manual examination
Number of subjects: 42
Study 35114058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebozo intervention before ECV (n=187)
Number of subjects: 372
Study 35114058 — intervention group
Group type: COMPARATOR
Intervention: Control group (ECV alone, n=185)
Number of subjects: 372
Study 33682192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-added formulas
Number of subjects: 83
Study 33682192 — intervention group
Group type: COMPARATOR
Intervention: Fiber-free formulas
Number of subjects: 83
Study 33682192 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diarrhea (any cause)
Number of subjects: 83
Study 33682192 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CDAD
Number of subjects: 83
Study 33682192 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication associated diarrhea
Number of subjects: 83
Study 33682192 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAD
Number of subjects: 83
Study 32439229 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM (thromboelastometry) guided therapy
Number of subjects: 92
Study 32439229 — intervention group
Group type: COMPARATOR
Intervention: Conventional laboratory tests (CLT)
Number of subjects: 92
Study 33568467 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 344
Study 32414376 — intervention group
Group type: COMPARATOR
Intervention: Basic educational materials alone (Arm 1)
Number of subjects: 23
Study 32414376 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic educational materials plus facilitation (Arm 2)
Number of subjects: 23
Study 35331018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (RT) at 70-80% of 1-repetition maximum (1-RM)
Number of subjects: 177
Study 35331018 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistance training (RT) at 40-50% of 1-repetition maximum (1-RM)
Number of subjects: 177
Study 35331018 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1200 International units vitamin D3 per day)
Number of subjects: 177
Study 35331018 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 177
Study 36331685 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRVB) intervention combined with treatment as usual
Number of subjects: 0
Study 36331685 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 0
Study 35728858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Calculation (IC) method
Number of subjects: 200
Study 35728858 — intervention group
Group type: COMPARATOR
Intervention: Traditional Calculation (TC) method
Number of subjects: 200
Study 33444219 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) early infant diagnosis (EID) test (Xpert HIV-1 Qualitative assay)
Number of subjects: 18
Study 34373214 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 60
Study 34373214 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment + medication
Number of subjects: 60
Study 34373214 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Number of subjects: 60
Study 34373214 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis + medication
Number of subjects: 60
Study 33802870 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention providing 8 weeks of tailored psychosocial support
Number of subjects: 0
Study 33802870 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0
Study 35051993 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Intervention for Safety Education (VRISE)
Number of subjects: 291
Study 35051993 — intervention group
Group type: COMPARATOR
Intervention: Control1: No treatment group
Number of subjects: 291
Study 35051993 — intervention group
Group type: COMPARATOR
Intervention: Control2: 2D Screen group
Number of subjects: 291
Study 33629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Number of subjects: 356
Study 33629189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 33629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX) and Placebo
Number of subjects: 356
Study 32240304 — intervention group
Group type: EXPERIMENTAL
Intervention: Plumpy'doz
Number of subjects: 3592
Study 32240304 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea
Number of subjects: 3592
Study 32240304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-lentil
Number of subjects: 3592
Study 32240304 — intervention group
Group type: EXPERIMENTAL
Intervention: WSB++
Number of subjects: 3592
Study 32240304 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3592
Study 35544042 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccine (3 × 105 to 1 × 108 pfu)
Number of subjects: 354
Study 35544042 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccine
Number of subjects: 354
Study 32979429 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 69
Study 32979429 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 69
Study 34273124 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit and vegetable consumption
Number of subjects: 240
Study 34273124 — intervention group
Group type: EXPERIMENTAL
Intervention: High fruit and vegetable consumption with high fat intake
Number of subjects: 240
Study 32406918 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 30
Study 32406918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 30
Study 35296253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic individualized PEEP titration (DV group)
Number of subjects: 51
Study 35296253 — intervention group
Group type: COMPARATOR
Intervention: Constant PEEP (PV group)
Number of subjects: 51
Study 35296253 — intervention group
Group type: COMPARATOR
Intervention: Zero PEEP (CV group)
Number of subjects: 51
Study 33422683 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 44
Study 33422683 — intervention group
Group type: COMPARATOR
Intervention: sham-stimulation
Number of subjects: 44
Study 35951718 — intervention group
Group type: EXPERIMENTAL
Intervention: Risuteganib (1.0 mg intravitreal injection)
Number of subjects: 39
Study 35951718 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 39
Study 33245129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program (food rations, BCC)
Number of subjects: 2620
Study 33245129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program (T18: food rations from pregnancy to 18 months)
Number of subjects: 2620
Study 33245129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program (T24: food rations from pregnancy to 24 months)
Number of subjects: 2620
Study 33245129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubaramure program (treatment arms combined)
Number of subjects: 2620
Study 33245129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rations or BCC)
Number of subjects: 2620
Study 35814746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided preoperative thoracic paravertebral blocks (TPVB)
Number of subjects: 100
Study 35814746 — intervention group
Group type: COMPARATOR
Intervention: Intercoastal nerve blocks (ICNB)
Number of subjects: 100
Study 34218329 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe-first group
Number of subjects: 358
Study 34218329 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)-first group
Number of subjects: 358
Study 32178978 — intervention group
Group type: EXPERIMENTAL
Intervention: VENTANA SP142
Number of subjects: 201
Study 32178978 — intervention group
Group type: EXPERIMENTAL
Intervention: VENTANA SP263
Number of subjects: 201
Study 32178978 — intervention group
Group type: EXPERIMENTAL
Intervention: DAKO 22C3
Number of subjects: 201
Study 32178978 — intervention group
Group type: EXPERIMENTAL
Intervention: DAKO 28-8
Number of subjects: 201
Study 32178978 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 assays
Number of subjects: 201
Study 35576276 — intervention group
Group type: EXPERIMENTAL
Intervention: Microporous tape applied to scars for six months, worn twenty-four hours daily, changed every fortnight.
Number of subjects: 0
Study 35576276 — intervention group
Group type: COMPARATOR
Intervention: Non-taped scars
Number of subjects: 0
Study 33509268 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT) and In‐service Teacher Training (INSETT)
Number of subjects: 350
Study 33509268 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (services as usual)
Number of subjects: 350
Study 32553596 — intervention group
Group type: EXPERIMENTAL
Intervention: IC injection of CD133+ BMSC
Number of subjects: 38
Study 32553596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 35247847 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of fish oil concentrate (providing 1.1 g eicosapentaenoic acid (EPA) + 0.8 g docosahexaenoic acid (DHA))
Number of subjects: 84
Study 35247847 — intervention group
Group type: COMPARATOR
Intervention: 3 g/day of corn oil
Number of subjects: 84
Study 34723443 — intervention group
Group type: EXPERIMENTAL
Intervention: HP4%
Number of subjects: 40
Study 34723443 — intervention group
Group type: EXPERIMENTAL
Intervention: MA + HP4%
Number of subjects: 40
Study 34723443 — intervention group
Group type: EXPERIMENTAL
Intervention: HP10%
Number of subjects: 40
Study 34723443 — intervention group
Group type: EXPERIMENTAL
Intervention: MA + HP10%
Number of subjects: 40
Study 33578519 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-video intervention via WeChat
Number of subjects: 78
Study 33578519 — intervention group
Group type: COMPARATOR
Intervention: Routine off-line instruction
Number of subjects: 78
Study 32122797 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO (robotic seal)
Number of subjects: 43
Study 32122797 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 34931276 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific EEG neurofeedback paradigm
Number of subjects: 39
Study 34931276 — intervention group
Group type: EXPERIMENTAL
Intervention: General EEG neurofeedback paradigm
Number of subjects: 39
Study 34931276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EEG neurofeedback paradigms
Number of subjects: 39
Study 33316077 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG subclasses presence
Number of subjects: 43
Study 33316077 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG2 subclass
Number of subjects: 43
Study 35850080 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 3 g/day
Number of subjects: 43
Study 35850080 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive Oil (OO) 3 g/day
Number of subjects: 43
Study 35850080 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 43
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to participant co‐morbidities
Number of subjects: 12
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to participant ability levels
Number of subjects: 12
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to ethics and consent
Number of subjects: 12
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to RCT methodology
Number of subjects: 12
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to gatekeeping
Number of subjects: 12
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to staff turnover
Number of subjects: 12
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to lack of technical understanding
Number of subjects: 12
Study 33277777 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges linked to attitudes and perceptions
Number of subjects: 12
Study 32193382 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful dietary pattern driven by wholemeal vs. white bread consumption
Number of subjects: 0
Study 32193382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary patterns derived from food frequency questionnaires
Number of subjects: 0
Study 34156877 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic nerve release during rotator cuff repair
Number of subjects: 42
Study 34156877 — intervention group
Group type: COMPARATOR
Intervention: Control group (arthroscopic repair of the rotator cuff without nerve release)
Number of subjects: 42
Study 32990630 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep‐Net intervention
Number of subjects: 235
Study 32990630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235
Study 34545613 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 finger‐tip unit equivalent dose of Hirudoid Cream 0.3% applied twice daily for 28 days
Number of subjects: 60